-
1Academic Journal
Συγγραφείς: Zh. B. Bibekova, E. A. Strel’cov, A. S. Makarchuk, Ж. Б. Бибекова, Е. А. Стрельцов, А. С. Макарчук
Πηγή: Medical Herald of the South of Russia; Том 11, № 1 (2020); 6-13 ; Медицинский вестник Юга России; Том 11, № 1 (2020); 6-13 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2020-11-1
Θεματικοί όροι: шизофрения, галоперидол деканоат, рисперидон, палиперидон пальмитат, арипипразол лауроксил, обзор
Περιγραφή αρχείου: application/pdf
Relation: https://www.medicalherald.ru/jour/article/view/1036/548; Karam C.S., Ballon J.S., Bivens N.M., Freyberg Z., Girgis R.R., et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. // Trends Pharmacol Sci. – 2010. – V.31(8). – P.381–90. doi:10.1016/j.tips.2010.05.004; Xu Y., Ren J., Ye H. Association between variations in the disrupted in schizophrenia 1 gene and schizophrenia: A metaanalysis. // Gene. – 2018. – V.651. – P.94–99. doi:10.1016/j. gene.2018.01.069.; National Institute of Mental Health Schizophrenia. Available online: https://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml. (accessed on 1 February 2016); Zhong X., Shi H., Hou L., Chen B., Peng Q., et al. Neuropsychiatric features of Neurosyphilis: frequency, relationship with the severity of cognitive impairment and comparison with Alzheimer disease. // Dement Geriatr Cogn Disord. – 2017. – V.43(5–6). – P.308–319. doi:10.1159/000476060.; Owen M.J., Sawa A., Mortensen P.B. Schizophrenia. // Lancet. – 2016. – V.388(10039). – P.86–97. doi:10.1016/S01406736(15)01121-6; Laursen T.M. Life expectancy among persons with schizophrenia or bipolar affective disorder. // Schizophr Res. – 2011. –; V.131(1–3). – P.101–4. doi:10.1016/j.schres.2011.06.008; Leng C.H., Chou M.H., Lin S.H., Yang Y.K., Wang J.D. Estimation of life expectancy, loss-of-life expectancy, and lifetime healthcare expenditures for schizophrenia in Taiwan. // Schizophr Res. – 2016. – V.171(1–3). – P.97–102. doi:10.1016/j.schres.2016.01.033; Olfson M., Gerhard T., Huang C., Crystal S., Stroup T.S. Premature Mortality Among Adults With Schizophrenia in the United States. // JAMA Psychiatry. – 2015. – V.72(12). – P.1172–81. doi:10.1001/jamapsychiatry.2015.1737; Walker E.R., McGee R.E., Druss B.G. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. // JAMA Psychiatry. - 2015. – V.72(4). – P.334–41. doi:10.1001/jamapsychiatry.2014.2502; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the global burden of disease study 2016. // Lancet. -; – V.390(10100). – P.1211–1259. doi:10.1016/S01406736(17)32154-2. 11. Robertson L. Mental Health Matters. Volume 4. - Health Service; Gauteng, South Africa; 2017.; Stringer J.L. Antipsychotics or Neuroleptics. In: Stringer J.L., ed. Basic Concepts in Pharmacology: What You Need to Know for Each Drug Class. 5th ed. McGraw-Hill; New York, NY, USA: Available at: http://accessmedicine.mhmedical.com/ content.aspx?bookid=2147§ionid=161351718. [accessed on 7 March 2019].; Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. // J Clin Psychiatry. – 2002. – V.63(10). – P.892–909. doi:10.4088/jcp.v63n1007; Ascher-Svanum H., Zhu B., Faries D.E., Salkever D., Slade E.P., et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. // BMC Psychiatry. -2010. – V.10. – P.2. doi:10.1186/1471-244X-10-2.; Di Lorenzo R., Ferri P., Cameli M., Rovesti S., Piemonte C. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a realworld clinical setting. // Neuropsychiatr Dis Treat. – 2019. – V.15. – P.183-198. doi:10.2147/NDT.S189245.; Gabriel R., Wojtanowicz T., Farokhpay R., Bota R. Acute transaminitis after initial days of starting haloperidol. // Ment Illn. – 2019. – V.11(1). – P.8113. doi:10.4081/mi.2019.8113.; European Medicines Agency. Haldol Decanoate and Associated Names: Assessment Report. 2017. Committee for Medicinal Products for Human Use (CHMP).) (EMA/217985/2017). Available at: http://www.ema.europa.eu [accessed on 7 March 2019].; Taylor D.M., Sparshatt A., O’Hagan M., Dzahini O. Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort - a four-year mirror image study. // Eur Psychiatry. – 2016. – V.37. – P.43–48. doi:10.1016/j.eurpsy.2016.04.009; McEvoy J.P., Byerly M., Hamer R.M., Dominik R., Swartz M.S., et all. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. // JAMA. – 2014. – V.311(19). – P.1978-87. doi:10.1001/jama.2014.4310.; Mace S., Dzahini O., O’Hagan M., Taylor D. Haloperidol decanoate long-acting injection (HDLAI): Results of a 1-year mirror-image study. // Ther Adv Psychopharmacol. – 2018. –V.8(9). – P.241-249. doi:10.1177/2045125318767587; Hori H., Katsuki A., Atake K., Yoshimura R. Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study. // Front Psychiatry. – 2018. – V.9. – P.74. doi:10.3389/fpsyt.2018.00074.; Mihaljevic-Peles A., Sagud M., Filipcic I.S., Grosic V., Pedisic I., Emsley R. Remission and employment status in schizophrenia and other psychoses: One-year prospective study in Croatian patients treated with risperidone long acting injection. // Psychiatr Danub. – 2016. – V.28(3). – P.263-272. PMID: 27658835 23. Giraud-Baro E., Dassa D., De Vathaire F., Garay R.P., Obeid J. Schizophrenia-spectrum patients treated with long-acting injectable risperidone in real-life clinical settings: functional recovery in remitted versus stable, non-remitted patients (the EVeREST prospective observational cohort study). // BMC Psychiatry. – 2016. – V.16. – P.8. doi:10.1186/s12888-0160712-1.; Jang S., Woo J. Five month-persistent extrapyramidal symptoms following a single injection of paliperidone palmitate: a case report. // Clinical Psychopharmacology and Neuroscience. – 2017. – V.15(3). – P.288–291. doi:10.9758/ cpn.2017.15.3.288; Emsley R., Parellada E., Bioque M., Herrera B., Hernando T., Garcia-Dorado M. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies. // Int Clin Psychopharmacol. – 2018. –; V.33(1). – P.15–33. doi:10.1097/YIC.000000000000019; Li N., Feng Y., Lu H., Cai S.L., Zhuo J., et al. Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics. // Neuropsychiatr Dis Treat. – 2018. – V.14. – P.825-837. doi:10.2147/NDT.S158353; Fernández-Miranda J.J., Díaz-Fernández S. Tolerability of effective high doses of paliperidone palmitate in patients with severe resistant schizophrenia. // International Clinical Psychopharmacology. – 2017. - V32(1). - P6–12. doi:10.1097/ YIC.0000000000000151; Si T., Zhuo J., Feng Y., Lu H., Hong D., Zhang L. Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia. // Neuropsychiatr Dis Treat. – 2019. – V.15. – P.1685-1694. doi:10.2147/NDT.S191803; Mathews M., Gopal S., Nuamah I., Hargarter L., Savitz A.J., et al. Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. // Neuropsychiatr Dis Treat. – 2019. – V.15. – P.1365-1379. doi:10.2147/NDT.S197225; Nash A.I., Turkoz I., Savitz A.J., Mathews M., Kim E. Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation. // Neuropsychiatr Dis Treat. – 2019. – V.15. – P.731-737. doi:10.2147/NDT.S194264; Mathews M., Nuamah I., Savitz A.J., Hough D.W., Najarian D., et al. Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. // Neuropsychiatr Dis Treat. – 2018. – V.14. – P.2807-2816. doi:10.2147/NDT.S175364; Gopal S., Vermeulen A., Nandy P., Ravenstijn P., Nuamah I., et al. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. // Current Medical Resident Opinion. – 2015. – V.31(11). – P.2043–2054. doi:10.1185/03007995.2015.1085849; Hard M.L., Wehr A.Y., Du Y., Weiden P.J., Walling D., von Moltke L. Pharmacokinetic evaluation of a 1-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia. // J Clin Psychopharmacol. – 2018. – V.38(5). – P.435–441. doi:10.1097/JCP.0000000000000921; McEvoy J.P., Risinger R., Mykhnyak S., Du Y., Liu C.C., Stanford A.D. Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia. // J Clin Psychiatry. – 2017. – V.78(8). – P.1103-1109. doi:10.4088/JCP.17m11625.; Risinger R., Hard M., Weiden P.J. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil. // Psychopharmacol Bull. – 2017. – V.47(3). – P.26-34. PMID: 28839337; Cameron C., Zummo J., Desai D.N., Drake C., Hutton B., Kotb A. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison. // Value Health. – 2017. – V.20(7). – P.876-885. doi:10.1016/j.jval.2017.03.010; Nasrallah H.A., Aquila R., Du Y., Stanford A.D., Claxton A., Weiden P.J. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia. // CNS Spectr. – 2019. – V.24(4). – P.395-403. doi:10.1017/S1092852918001104; Mogwitz S., Buse J., Wolff N., Roessner V. Update on the Pharmacological Treatment of Tics with DopamineModulating Agents. // ACS Chem Neurosci. – 2018. – V.9(4). – P.651-672. doi:10.1021/acschemneuro.7b00460; Zhao Y.J., Lin L., Teng M., Khoo A.L., Soh L.B., et al. Longterm antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. // BJPsych Open. – 2016. – V.2(1). – P.59-66. doi:10.1192/bjpo.bp.115.002576; Maayan N., Quraishi S.N., David A., Jayaswal A., Eisenbruch M., et al. Fluphenazine decanoate (depot) and enanthate for schizophrenia. // Cochrane Database Syst Rev. – 2015. – V.(2). – P.CD000307. doi:10.1002/14651858.CD000307.pub2.; Coutinho E., Fenton M., Quraishi S. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. // Cochrane Database Syst Rev. – 2000. – V.(2). – P.CD001164. doi:10.1002/14651858.CD001164; Mahapatra J., Quraishi S.N., David A., Sampson S., Adams C.E. Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. // Cochrane Database Syst Rev. – 2014. – V.(6). – P.CD001470. doi:10.1002/14651858. CD001470.pub2.; Zyprexa [package Insert]. Indianapolis (IN): Eli Lilly and Company; 2018.; Fefeu M, De Maricourt P, Cachia A, Hoertel N, Vacheron MN, et al. One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia. // Psychiatry Res. – 2018. – V.270. – P.205-210. doi:10.1016/j.psychres.2018.09.041.; Kane J.M., Detke H.C., Naber D., Sethuraman G., Lin D.Y., Bergstrom R.F. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. // Am J Psychiatry. – 2010. – V.167(2). – P.181-9. doi:10.1176/appi.ajp.2009.07081221.; https://www.medicalherald.ru/jour/article/view/1036
-
2Academic Journal
Συγγραφείς: Любов, Евгений, Фролов, Максим, Чапурин, Сергей, Чурилин, Юрий
Θεματικοί όροι: ИНЪЕКЦИОННЫЕ ПРЕПАРАТЫ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ, ПАЛИПЕРИДОН ПАЛЬМИТАТ, МАРКОВСКАЯ МОДЕЛЬ ПРИНЯТИЯ РЕШЕНИЯ
Περιγραφή αρχείου: text/html
-
3Academic Journal
Πηγή: Социальная и клиническая психиатрия.
Θεματικοί όροι: ИНЪЕКЦИОННЫЕ ПРЕПАРАТЫ ДЛИТЕЛЬНОГО ДЕЙСТВИЯ, ПАЛИПЕРИДОН ПАЛЬМИТАТ, МАРКОВСКАЯ МОДЕЛЬ ПРИНЯТИЯ РЕШЕНИЯ, 3. Good health
Περιγραφή αρχείου: text/html
